Skip to content

Role of Mesocorticolimbic Pathway in Apathy of Patients With Parkinson's Disease. - Study Using Diffusion Tensor Imaging and Fibres Tracking

Role of Mesocorticolimbic Pathway in Apathy of Patients With Parkinson's Disease. - Study Using Diffusion Tensor Imaging and Fibres Tracking

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01794195
Enrollment
63
Registered
2013-02-18
Start date
2013-02-28
Completion date
2013-12-31
Last updated
2014-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apathy, Parkinson's Disease

Keywords

Parkinson's disease, Apathy, diffusion tensor imaging, tractography

Brief summary

Use lay language. Apathy is one of the most under recognised, underdiagnosed and poorly managed aspects of Parkinson's disease. Depending on methodological approach of the study, its prevalence is estimated to be between 16 and 51%. Apathy derives from a dysfunction of the dopaminergic meso cortico limbic systems, which seems to play a central role in the control of mood and motivation. The subcortical components of this system are the ventral tegmental area (VTA), the nucleus accumbens, and the constituents of the limbic system (particularly the hippocampus and amygdala), all of which are located deep inside the brain (18). The hypothesis is that depletion of striatal dopamine from regulators located in the midbrain (VTA and SNpc) in striato-thalamo-cortical circuits results in hypofunction of these circuits and the loss of frontal cortical activity, particularly within in the frontal orbital cortex, the anterior cingulate cortex and the prefrontal cortex The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods

Detailed description

3 groups : * 20 apathetic patients with Parkinson's disease * 20 non apathetic paired patients) * 20 healthy paired control Description of the protocol for patients : J0 : Inclusion visit (duration : 4h): * motor assessment (UPDRS) * neuropsychological and psychiatric assessment : Cognitive assessments : Mini Mental State MMS, MATTIS Apathy assessment: Apathy Inventory from Robert et al (2002); Lille apathy rating scale (LARS) ; Starkstein scale. Depression assessment : Montgomery et Alsberg depression rating scale (MADRS) J0+1 day : MRI (magnetic resonance imaging) acquisition (30 minutes) Multimodal MRI examinations will be performed (Diffusion-weighted data and high-resolution 3-dimensional (3D) T1- weighted as well as T2-weighted images) on each subject on a GE 3-T.

Interventions

BEHAVIORALDiffusion tensor imaging and fibres tracking

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

\- Patients : * Men or women aged between 18 -85 years * Patients with an idiopathic Parkinson's disease according to UKPDSBB criterias * Non dement (MMS ≥ 26 ; MATTIS ≥ 130) * Affiliated to National Health system * Having given their informed consent Healthy controls * Men or women aged between 18 -85 years * Affiliated to National Health system * Having given their informed consent

Exclusion criteria

* Patients : * Patients suffering of an atypical Parkinson syndrome * Psychiatric pathology * Severe tremor form of PD * Depression (MADRS \>16)., dementia (MMS \< 26, MATTIS \< 130). * Pregnant * Under guardianship * In excluding period for another study * Any contra-indication to MRI Healthy subject * Subject with neurological, psychiatric diseases * Depression, dementia, apathy * Pregnant * Under guardianship * In excluding period for another study * Any contra-indication to MRI

Design outcomes

Primary

MeasureTime frame
Fractional anisotropy coefficient (the fractional anisotropy coefficient is computed from the eigenvalues of the diffusion tensor)at day 1

Secondary

MeasureTime frame
Fibres density (number of fibres / voxel)at day 1
Bulk diffusivity indexat day 1
Apparent diffusion coefficientat day 1

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026